必贝特公告称，公司首次公开发行股票并在科创板上市的申请已获上交所上市审核委员会审议通过，并 获中国证监会同意注册。本次公开发行股票9000万股，占发行后总股本的20%，发行价格为17.78元/ 股，募集资金总额16.00亿元。保荐人相关子公司中证投资参与战略配售，获配337.46万股，金额 6000.00万元，限售期24个月。发行费用合计1.09亿元。 ...

Core Points - The company guarantees the authenticity, accuracy, and completeness of the quarterly report, and assumes legal responsibility for its content [1] - The quarterly financial report has not been audited [2] - The net profit attributable to shareholders increased by 2.77% year-on-year, while the net profit excluding non-recurring gains and losses grew by 4.69% year-on-year [2] Financial Data - The report period refers to the three months from the beginning to the end of the quarter [2] - The company recognized a total of 13.2962 million yuan in stock incentive expenses from the beginning of the year to the end of the reporting period [2] - The company’s repurchase account held 2,179,346 shares, accounting for 1.23% of the total share capital of 176,532,256 shares as of the end of the reporting period [5] Shareholder Information - There are no changes in the borrowing or returning of shares by the top ten shareholders due to transfer and financing [6] - The report does not include any additional important information regarding the company's operational situation during the reporting period [6]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688278证券简称：特宝生物公告编号：2025-039 厦门特宝生物工程股份有限公司 2024年限制性股票激励计划首次授予部分 第一个归属期归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为1,389,480股。 本次股票上市流通总数为1,389,480股。 ●本次股票上市流通日期为2025年10月30日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责任公司上海分公司有关业务 规则的规定，厦门特宝生物工程股份有限公司（以下简称"公司"）于2025年10月27日收到中国证券登记 结算有限责任公司上海分公司出具的《证券变更登记证明》，公司完成了2024年限制性股票激励计划 （以下简称"本激励计划"）首次授予部分第一个归属期的股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 1、2024年8月21日，公司召开第 ...

Core Points - Suzhou Fengbei Biotechnology Co., Ltd. has received approval for its initial public offering (IPO) of RMB ordinary shares (A-shares) and listing on the main board from the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][2] - The total number of shares for this issuance is set at 35.9 million, with an initial strategic placement of 7.18 million shares, accounting for 20% of the total issuance [2] - The final strategic placement quantity is 4.083297 million shares, which is 11.37% of the total issuance, with the difference being allocated to offline issuance [2] Issuance Structure - The issuance will combine strategic placement, offline pricing for qualified investors, and online pricing for public investors holding non-restricted A-shares and depository receipts [1] - After the strategic placement adjustment, the offline issuance will consist of 20.328703 million shares (63.89% of the remaining shares), while the online issuance will consist of 11.488 million shares (36.11% of the remaining shares) [2][7] Pricing and Payment - The issuance price is set at RMB 24.49 per share, with the online offering of 11.488 million shares scheduled for October 27, 2025 [2] - Investors must fulfill their payment obligations by October 29, 2025, with specific instructions for offline and online investors regarding payment procedures [3][4] Subscription and Allocation - The initial online subscription saw 13,647,883 valid applications, totaling 101,265,777,500 shares, resulting in an initial online winning rate of 0.01134441% [6] - Following the implementation of the allocation mechanism, the final online winning rate increased to 0.02391232% after reallocating shares from offline to online due to high demand [8] Draw and Announcement - The online draw for the issuance is scheduled for October 28, 2025, with results to be announced on October 29, 2025 [9]

Group 1 - Newman Mining is considering acquiring Barrick Gold's Nevada gold mine assets, currently holding a minority stake in the joint venture and exploring various transaction options [1] - Eli Lilly plans to acquire gene therapy company Adverum for $3.56 per share, with potential additional value of up to $8.91 per share based on specific conditions [2] - Qingdao Beer has terminated its acquisition of 100% equity in Jimo Yellow Wine due to unmet conditions in the equity transfer agreement, incurring no liability [3] Group 2 - China Tungsten High-Tech plans to acquire 99.9733% equity in Hunan Yuanjing Tungsten Industry for 821 million yuan, constituting a related party transaction but not a major asset restructuring [4] - Skyworth Group intends to acquire a 40% stake in Fengchi Electronics for 116 million yuan and will inject an additional 104 million yuan into the company [5] - Yayi Chemical Group is set to acquire approximately 60% equity in Beijing Xinnuo Haibo Petrochemical Technology, a leading chemical gas company in China [6] Group 3 - Shandong Steel plans to acquire 100% equity in Laiwu Steel Group Yingshan Type Steel for 714 million yuan, making it a wholly-owned subsidiary [7] - Weston intends to acquire 36.748% of Liangtou Technology for 106.7 million yuan and will inject an additional 53.27 million yuan into the company [8] - Delong Holdings' major shareholder plans to transfer 29.64% of its shares to Dongyang Noxin Chip Materials, potentially leading to a change in control [9] Group 4 - Jinchun Co. plans to acquire 51% equity in Jincheng Source Material Technology for 51.918 million yuan, making it a controlling subsidiary [10] - Shenlian Biology's subsidiary has completed an investment to gain control over the joint venture Shizhi Yuan, which will be consolidated into Shenlian's financial statements [11] - Fuda Alloy intends to acquire 52.61% of Zhejiang Guangda Electronics for 352 million yuan, which is expected to increase total assets but also raise the debt ratio by over 10 percentage points to 77.23% [12] Group 5 - Suzhou Planning and Design Institute has completed the acquisition of 80% equity in Kunshan Development Zone Architectural Design Institute for 6.6537 million yuan [13] - Yingtang Intelligent Control plans to acquire 100% of Guilin Guanglong Integrated Technology and 76% of Shanghai Aojian Microelectronics through a combination of stock issuance and cash payment [14] - Novartis has announced the acquisition of Avidity Biosciences, focusing on RNA therapy delivery to muscle tissues [15] Group 6 - WuXi AppTec plans to sell equity in its subsidiary to Hillhouse Capital for a base price of 2.8 billion yuan [16]

Core Viewpoint - Shuyou Shen (300204) plans to issue shares to specific investors to raise up to 1.253 billion yuan for innovative drug research and working capital, following approval from the board and shareholders [3][5]. Group 1: Financial Performance - As of December 31, 2024, the company's total consolidated assets amounted to 1,149.61 million yuan, with total liabilities of 232.85 million yuan and equity attributable to shareholders of 929.23 million yuan [2]. - For the fiscal year 2024, the company reported a consolidated revenue of 324.82 million yuan and a net loss of 147.73 million yuan, with a negative cash flow from operating activities of 63.68 million yuan [2]. - The company has experienced continuous net losses over the past three years, with a net loss of 24.64 million yuan in the first half of 2025 [4]. Group 2: Stock Issuance Details - The planned share issuance will not exceed 143,331,766 shares, representing 30% of the total share capital prior to the issuance, with a minimum issuance price set at 80% of the average trading price over the previous 20 trading days [3][5]. - The funds raised will be allocated as follows: 883 million yuan for clinical research and registration of innovative drugs (BDB-001, STSA-1002, STSP-0902) and 370 million yuan for working capital [5]. - The issuance is subject to approval from the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission [4][5]. Group 3: Market Activity - On October 27, 2025, Shuyou Shen's stock closed at 34.13 yuan, with a trading volume of 342,800 shares and a turnover of 1.189 billion yuan [1]. - The net outflow of funds from major investors on the same day was 57.71 million yuan, while retail investors saw a net inflow of 95.75 million yuan [2][4].

Group 1 - The core point of the article is that Boya Bio (SZ 300294) held its 16th meeting of the 8th Board of Directors on October 27, 2025, to review the performance contracts for the management team for the year 2025 [1] - For the first half of 2025, Boya Bio's revenue composition is as follows: blood products account for 84.58%, biochemical drugs for 8.63%, pharmaceutical distribution for 6.12%, other industries for 0.65%, and other businesses for 0.02% [1] - As of the report date, Boya Bio has a market capitalization of 12.4 billion yuan [1]

Group 1 - Watson Bio has received approval from the National Medical Products Administration for a clinical trial of its respiratory syncytial virus mRNA vaccine, developed in collaboration with Fudan University and other partners [1] - The approval allows for clinical trials aimed at preventing lower respiratory tract diseases caused by respiratory syncytial virus, with a validity period of three years for the trial implementation [1] - As of the first half of 2025, Watson Bio's revenue composition shows that self-developed vaccines account for 94.82%, intermediate product revenue for 4.67%, and other business segments for 0.50% [1] Group 2 - The company has a market capitalization of 18.1 billion yuan [1]

Group 1: Meituan's Health Initiative - Meituan has launched a "Health Double Eleven" campaign featuring special medical foods and health supplements, responding to a nearly 40% increase in related search volume on its platform [1] - The campaign includes products like Ejiao and bird's nest, along with special medical foods such as Ai Er Shu and Tai Min Shu, and offers significant discount coupons to users [1] - Users purchasing special medical foods can join a community for exclusive nutritionist consultations and additional discounts [1] Group 2: Qingdao Beer Financial Performance - Qingdao Beer reported a third-quarter net profit of 1.37 billion yuan, representing a year-on-year increase of 1.62% [2] - The company's revenue for the third quarter was 8.876 billion yuan, showing a slight decline of 0.17% compared to the previous year [2] Group 3: Changchun High-tech's Clinical Trial Approval - Changchun High-tech's subsidiary, GenSci, received approval for the clinical trial application of GenSci098 injection, which has potential for treating diffuse toxic goiter [3] - This approval is expected to facilitate the clinical development of the product for the target population [3] Group 4: Kingsoft Office Financial Performance - Kingsoft Office reported a third-quarter net profit of 431 million yuan, marking a year-on-year increase of 35.42% [4] - The company's revenue for the third quarter was 1.521 billion yuan, reflecting a growth of 25.33% year-on-year [4] Group 5: Foreign Exchange and Trade Statistics - In the first three quarters, China's foreign exchange receipts and payments reached 11.6 trillion USD, setting a record for the same period [5] - The foreign exchange market transaction volume is projected to grow by 37% in 2024 compared to 2020, with foreign exchange receipts increasing by 64% over the same period [5] Group 6: Three Squirrels Financial Performance - Three Squirrels reported a third-quarter net profit of 22.27 million yuan, which is a significant decline of 56.79% year-on-year [6] - The company's revenue for the third quarter was 2.281 billion yuan, showing an increase of 8.91% compared to the previous year [6] Group 7: Hengrui Medicine Financial Performance - Hengrui Medicine's third-quarter revenue was 7.427 billion yuan, reflecting a year-on-year growth of 12.72% [6] - The net profit for the third quarter was 1.301 billion yuan, which is a 9.53% increase year-on-year [6] Group 8: Anta Sports Retail Performance - Anta Sports reported low single-digit growth in retail sales for its Anta and FILA brands in the third quarter [9] - Other brands under the company achieved a significant retail sales growth of 45-50% year-on-year [9] Group 9: National Airlines Aircraft Purchase - National Airlines announced plans to purchase six A350F cargo aircraft from Airbus, with an option for four additional aircraft [10] - The total value of the aircraft, based on the January 2024 catalog price, is approximately 4.65 billion USD per unit, with potential discounts negotiated [10] Group 10: Investment and Financing Activities - Guoyi Quantum has completed a new round of strategic financing led by Hefei Xingtai Capital, aimed at enhancing its R&D capabilities in quantum computing and related fields [10] - Song Yang has replaced Shao Jingping as the head of JD Retail's marketing center, following Shao's departure for personal reasons [7] Group 11: New Product Launch by Meituan - Meituan's LongCat team has released and open-sourced the LongCat-Video video generation model, achieving state-of-the-art results in video generation tasks [10] - The model aims to enhance capabilities in various applications, including autonomous driving and interactive business scenarios [10] Group 12: Regulatory Changes in Foreign Investment - The China Securities Regulatory Commission has introduced a green channel and simplified processes for foreign institutional investors, including sovereign funds and pension funds [11]

Group 1: Company Performance - Meituan's special medical food activity section launched for Double Eleven, with a nearly 40% week-on-week increase in related search volume [1] - Qingdao Beer reported a third-quarter net profit of 1.37 billion, a year-on-year increase of 1.62%, with revenue of 8.876 billion, a slight decline of 0.17% [2] - Changchun High-tech's subsidiary received approval for clinical trials of GenSci098 injection, which has potential for treating diffuse toxic goiter [3] - Kingsoft Office reported a third-quarter net profit of 431 million, a year-on-year increase of 35.42%, with revenue of 1.521 billion, up 25.33% [4] - Anta Sports reported low single-digit growth in retail sales for Anta and FILA brands in the third quarter, while other brands saw a 45-50% increase [9] - Heng Rui Pharmaceutical reported a third-quarter net profit of 1.301 billion, a year-on-year increase of 9.53%, with revenue of 7.427 billion, up 12.72% [6] - Three Squirrels reported a third-quarter net profit of 22.27 million, a year-on-year decrease of 56.79%, with revenue of 2.281 billion, up 8.91% [5] - Kangtai Biological reported a third-quarter net profit of 11.62 million, a year-on-year decrease of 93.74%, with revenue of 671 million, down 17.74% [8] Group 2: Investment and Financing - Guoyi Quantum received strategic investment from Hefei Xingtai Capital, which will enhance its R&D capabilities in quantum computing and related fields [10] - Song Yang has replaced Shao Jingping as the head of JD Retail Platform Marketing Center due to personal reasons [7] - Song Yan Power completed nearly 300 million Pre-B round financing led by Fanggu Capital, with participation from several other investors [11] Group 3: Market Trends and Economic Indicators - China's foreign exchange revenue and expenditure scale reached 11.6 trillion in the first three quarters, a historical high, with a 37% increase in trading volume compared to 2020 [5] - The China Securities Regulatory Commission has implemented a green channel and simplified processes for foreign investment from sovereign funds, international organizations, and pension charitable funds [12] Group 4: New Products - Meituan LongCat-Video was officially released and open-sourced, achieving state-of-the-art performance in video generation tasks [11]